Ethyl eicosapentaenoic acid/niacin - Amarin

Drug Profile

Ethyl eicosapentaenoic acid/niacin - Amarin

Latest Information Update: 23 Apr 2011

Price : $50

At a glance

  • Originator Amarin Corporation
  • Class
  • Mechanism of Action GPR109A receptor agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 29 Nov 2007 Phase-I clinical trials in Hyperlipidaemia in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top